Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...
The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...
A single-center study suggests complement inhibitors do not reduce the severity of a COVID-19 Omicron infection in patients with paroxysmal nocturnal hemoglobinuria (PNH). A COVID-19 infection can ...
A new study may offer a strategy that mitigates negative side effects associated with intravenous injection of nanoparticles commonly used in medicine. The study was published today in Nature ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results